Ebola GP-specific monoclonal antibodies protect mice and guinea pigs from lethal Ebola virus infection

PLoS Neglected Tropical Diseases

Volumn 6, Issue 3, 2012, Pages

  Qiu, Xiangguo ^a   Fernando, Lisa ^a   Melito, P Leno ^a   Audet, Jonathan ^a,b   Feldmann, Heinz ^a,b,c   Kobinger, Gary ^a,b   Alimonti, Judie B ^a,b   Jones, Steven M ^a,b,d  

^a PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d Cognoveritas Consulting Inc ^*  (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EBOLA VIRUS ANTIBODY; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY; ENVELOPE GLYCOPROTEIN, EBOLA VIRUS; VIRUS ENVELOPE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; EBOLA HEMORRHAGIC FEVER; EBOLA VIRUS; FEMALE; GUINEA PIG; IMMUNIZATION; LD 50; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTECTION; SINGLE DRUG DOSE; SURVIVAL; ANIMAL; BAGG ALBINO MOUSE; IMMUNOLOGY; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; EBOLAVIRUS; FEMALE; GUINEA PIGS; HEMORRHAGIC FEVER, EBOLA; MICE; MICE, INBRED BALB C; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VIRAL ENVELOPE PROTEINS;

EID: 84859206023     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0001575     Document Type: Article

References (42)

1. Sanchez A, Geisbert TW, Feldmann H, (2007) Filoviridae: Marburg and ebola viruses. In: Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, editors. Fields Virology Lippincott, Williams & Wilkins pp. 1409-1448.
2. Towner JS, Sealy TK, Khristova ML, Albarino CG, Conlan S, et al. (2008) Newly discovered ebola virus associated with hemorrhagic fever outbreak in uganda. PLoS Pathog 4 (11): e1000212.
3. Feldmann H, Geisbert TW, (2010) Ebola haemorrhagic fever. Lancet.
4. Feldmann H, Jones SM, Daddario-Dicaprio KM, Geisbert JB, Stroher U, et al. (2007) Effective post-exposure treatment of ebola infection. PLoS Pathog 3 (1): e2.
5. Geisbert TW, Hensley LE, Jahrling PB, Larsen T, Geisbert JB, et al. (2003) Treatment of ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: A study in rhesus monkeys. Lancet 362 (9400): 1953-1958.
6. Hensley LE, Stevens EL, Yan SB, Geisbert JB, Macias WL, et al. (2007) Recombinant human activated protein C for the postexposure treatment of ebola hemorrhagic fever. J Infect Dis 196 (Suppl 2): S390-9.
7. Geisbert TW, Lee AC, Robbins M, Geisbert JB, Honko AN, et al. (2010) Postexposure protection of non-human primates against a lethal ebola virus challenge with RNA interference: A proof-of-concept study. Lancet 375 (9729): 1896-1905.
8. Warfield KL, Swenson DL, Olinger GG, Nichols DK, Pratt WD, et al. (2006) Gene-specific countermeasures against ebola virus based on antisense phosphorodiamidate morpholino oligomers. PLoS Pathog 2 (1): e1.
9. Qiu X, Fernando L, Alimonti JB, Melito PL, Feldmann F, et al. (2009) Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses. PLoS One 4 (5): e5547.
10. Jahrling PB, Geisbert JB, Swearengen JR, Larsen T, Geisbert TW, (2007) Ebola hemorrhagic fever: Evaluation of passive immunotherapy in nonhuman primates. J Infect Dis 196 (Suppl 2): S400-3.
11. Bradfute SB, Braun DR, Shamblin JD, Geisbert JB, Paragas J, et al. (2007) Lymphocyte death in a mouse model of ebola virus infection. J Infect Dis 196 (Suppl 2): S296-304.
12. Rubins KH, Hensley LE, Wahl-Jensen V, Daddario DiCaprio KM, Young HA, et al. (2007) The temporal program of peripheral blood gene expression in the response of nonhuman primates to ebola hemorrhagic fever. Genome Biol 8 (8): R174.
13. Cilloniz C, Ebihara H, Ni C, Neumann G, Korth MJ, et al. (2011) Functional genomics reveals the induction of inflammatory response and metalloproteinase gene expression during lethal ebola virus infection. J Virol 85 (17): 9060-9068.
14. Gupta M, Greer P, Mahanty S, Shieh WJ, Zaki SR, et al. (2005) CD8-mediated protection against ebola virus infection is perforin dependent. J Immunol 174 (7): 4198-4202.
15. Warfield KL, Perkins JG, Swenson DL, Deal EM, Bosio CM, et al. (2004) Role of natural killer cells in innate protection against lethal ebola virus infection. J Exp Med 200 (2): 169-179.
16. Baize S, Leroy EM, Georges-Courbot MC, Capron M, Lansoud-Soukate J, et al. (1999) Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in ebola virus-infected patients. Nat Med 5 (4): 423-426.
17. Ksiazek TG, Rollin PE, Williams AJ, Bressler DS, Martin ML, et al. (1999) Clinical virology of ebola hemorrhagic fever (EHF): Virus, virus antigen, and IgG and IgM antibody findings among EHF patients in kikwit, democratic republic of the congo, 1995. J Infect Dis 179 (Suppl 1): S177-87.
18. Jones SM, Stroher U, Fernando L, Qiu X, Alimonti J, et al. (2007) Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of ebola virus hemorrhagic fever. J Infect Dis 196 (Suppl 2): S404-12.
19. Gupta M, Mahanty S, Bray M, Ahmed R, Rollin PE, (2001) Passive transfer of antibodies protects immunocompetent and imunodeficient mice against lethal ebola virus infection without complete inhibition of viral replication. J Virol 75 (10): 4649-4654.
20. Feldmann H, Volchkov VE, Volchkova VA, Stroher U, Klenk HD, (2001) Biosynthesis and role of filoviral glycoproteins. J Gen Virol 82 (Pt 12): 2839-2848.
21. Feldmann H, Volchkov VE, Volchkova VA, Klenk HD, (1999) The glycoproteins of marburg and ebola virus and their potential roles in pathogenesis. Arch Virol Suppl 15: 159-169.
22. Alazard-Dany N, Volchkova V, Reynard O, Carbonnelle C, Dolnik O, et al. (2006) Ebola virus glycoprotein GP is not cytotoxic when expressed constitutively at a moderate level. J Gen Virol 87 (Pt 5): 1247-1257.
23. Yonezawa A, Cavrois M, Greene WC, (2005) Studies of ebola virus glycoprotein-mediated entry and fusion by using pseudotyped human immunodeficiency virus type 1 virions: Involvement of cytoskeletal proteins and enhancement by tumor necrosis factor alpha. J Virol 79 (2): 918-926.
24. Wahl-Jensen VM, Afanasieva TA, Seebach J, Stroher U, Feldmann H, et al. (2005) Effects of ebola virus glycoproteins on endothelial cell activation and barrier function. J Virol 79 (16): 10442-10450.
25. Maruyama T, Rodriguez LL, Jahrling PB, Sanchez A, Khan AS, et al. (1999) Ebola virus can be effectively neutralized by antibody produced in natural human infection. J Virol 73 (7): 6024-6030.
26. Oswald WB, Geisbert TW, Davis KJ, Geisbert JB, Sullivan NJ, et al. (2007) Neutralizing antibody fails to impact the course of ebola virus infection in monkeys. PLoS Pathog 3 (1): e9.
27. Wilson JA, Hevey M, Bakken R, Guest S, Bray M, et al. (2000) Epitopes involved in antibody-mediated protection from ebola virus. Science 287 (5458): 1664-1666.
28. Yang ZY, Duckers HJ, Sullivan NJ, Sanchez A, Nabel EG, et al. (2000) Identification of the ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury. Nat Med 6 (8): 886-889.
29. Volchkov VE, Volchkova VA, Muhlberger E, Kolesnikova LV, Weik M, et al. (2001) Recovery of infectious ebola virus from complementary DNA: RNA editing of the GP gene and viral cytotoxicity. Science 291 (5510): 1965-1969.
30. Simmons G, Wool-Lewis RJ, Baribaud F, Netter RC, Bates P, (2002) Ebola virus glycoproteins induce global surface protein down-modulation and loss of cell adherence. J Virol 76 (5): 2518-2528.
31. Shahhosseini S, Das D, Qiu X, Feldmann H, Jones SM, et al. (2007) Production and characterization of monoclonal antibodies against different epitopes of ebola virus antigens. J Virol Methods 143 (1): 29-37.
32. Takada A, Ebihara H, Feldmann H, Geisbert TW, Kawaoka Y, (2007) Epitopes required for antibody-dependent enhancement of ebola virus infection. J Infect Dis 196 (Suppl 2): S347-56.
33. Takada A, Ebihara H, Jones S, Feldmann H, Kawaoka Y, (2007) Protective efficacy of neutralizing antibodies against ebola virus infection. Vaccine 25 (6): 993-999.
34. Lucht A, Grunow R, Otterbein C, Moller P, Feldmann H, et al. (2004) Production of monoclonal antibodies and development of an antigen capture ELISA directed against the envelope glycoprotein GP of ebola virus. Med Microbiol Immunol 193 (4): 181-187.
35. Parren PW, Geisbert TW, Maruyama T, Jahrling PB, Burton DR, (2002) Pre- and postexposure prophylaxis of ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. J Virol 76 (12): 6408-6412.
36. Qiu X, Alimonti JB, Melito PL, Fernando L, Stroher U, et al. (2011) Characterization of zaire ebolavirus glycoprotein-specific monoclonal antibodies. Clin Immunol in press.
37. Garbutt M, Liebscher R, Wahl-Jensen V, Jones S, Moller P, et al. (2004) Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol 78 (10): 5458-5465.
38. Bray M, Davis K, Geisbert T, Schmaljohn C, Huggins J, (1998) A mouse model for evaluation of prophylaxis and therapy of ebola hemorrhagic fever. J Infect Dis 178 (3): 651-661.
39. Connolly BM, Steele KE, Davis KJ, Geisbert TW, Kell WM, et al. (1999) Pathogenesis of experimental ebola virus infection in guinea pigs. J Infect Dis 179 (Suppl 1): S203-17.
40. Kohler G, Milstein C, (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256 (5517): 495-497.
41. Wahl-Jensen V, Kurz SK, Hazelton PR, Schnittler HJ, Stroher U, et al. (2005) Role of ebola virus secreted glycoproteins and virus-like particles in activation of human macrophages. J Virol 79 (4): 2413-2419.
42. Shedlock DJ, Bailey MA, Popernack PM, Cunningham JM, Burton DR, et al. (2010) Antibody-mediated neutralization of ebola virus can occur by two distinct mechanisms. Virology 401 (2): 228-235.